ArticleBlood cancer journal2022

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide.

Carmelo Gurnari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.